Project measures / variables set:   CSNA03   dist_f30_cont_cc

ID, description, units MPD:90329   dist_f30_cont_cc   distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]  
Measures
• day:    • 1    • 2    • 3    • 5    • 7    • 9    • 11    • 12    • 19
Data set, strains CSNA03   CC w/par   58 strains     sex: both     age: 8-21wks
Procedure open field test
Comparisontimecourse, same cohort
Ontology mappings

  SIDE-BY-SIDE STRAIN CURVES
Values
Graph Type
Dimensions Width:  ×  Height: px
Plot Options


  OVERLAPPING STRAIN CURVES
Data
Dimensions px
Toggle Series   
Plot Options
Advanced Plot Options
Separate Plot Factor(s)
Legend Factor(s)
X-Axis Factor(s)
Include/Exclude Factor Values

CSNA03 - distance traveled, first 30 min (pre-injection), on successive days, saline group, CC


  ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary          "within" = Within error     "between" = Between Error (Animal ID)

Factor DF Sum of squares Mean sum of squares F value p-value (Pr>F)
within   day 8 607724060.8136 75965507.6017 10.5401 < 0.0001
within   day:sex 8 21682017.3113 2710252.1639 0.376 0.9337
within   day:strain 336 2414383270.7668 7185664.4963 0.997 0.5065
within   day:sex:strain 336 1278424564.9073 3804835.0146 0.5279 1.0
within   Residuals 1992 14356897785.9298 7207278.005
between   sex 1 1745668698.4586 1745668698.4586 32.556 < 0.0001
between   strain 42 30275343104.9449 720841502.4987 13.4434 < 0.0001
between   sex:strain 42 2798126489.5615 66622059.2753 1.2425 0.1592
between   Residuals 249 13351494410.7462 53620459.4809

Q-Q normality assessment based on residuals

  


  INDIVIDUAL MEASURES
ProjectIDTreatmentMeasure / Variable Description PanelStrains
tested		SexAge
CSNA03 90329 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 1  dist_f30_cont_cc_d1 CC w/par 58 both 8-21wks
CSNA03 90335 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 2  dist_f30_cont_cc_d2 CC w/par 58 both 8-21wks
CSNA03 90341 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 3  dist_f30_cont_cc_d3 CC w/par 58 both 8-21wks
CSNA03 90347 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 5  dist_f30_cont_cc_d5 CC w/par 58 both 8-21wks
CSNA03 90353 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 7  dist_f30_cont_cc_d7 CC w/par 58 both 8-21wks
CSNA03 90359 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 9  dist_f30_cont_cc_d9 CC w/par 58 both 8-21wks
CSNA03 90365 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 11  dist_f30_cont_cc_d11 CC w/par 58 both 8-21wks
CSNA03 90371 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 12  dist_f30_cont_cc_d12 CC w/par 58 both 8-21wks
CSNA03 90377 open field test (none) distance traveled, first 30 min (pre-injection), on successive days, saline group, CC   [cm]   day 19  dist_f30_cont_cc_d19 CC w/par 58 both 8-21wks



  •   Or, add these measures to your collection.
       
  •     no folder
  •     put them in new folder